Watch: Another TYK2 Ticks the Boxes Dr. Janet Pope discusses late-breaking abstract L12 presented at #ACR23. https://t.co/1SGuIFOWt6 https://t.co/tb4LRbmfiI

• Another TYK2 Ticks the Boxes | RheumNow

JAKi, especially BARI, may be useful and safe in controlling both pulmonary and joint disease in RA-ILD patients, even in refractory cases. Evolution of FVC and DLCO remained stable in first 12 months. Serrano-Combarro A, Abst#2174 #ACR23 @RheumNow https://t.co/82mMn5oh15 https://t.co/e7wrgmTOTA

Serrano-Combarro et al. JAKi in RA-ILD. 73 patients on JAKi (74% Bari). Many had prev received abatacept/rituximab. HRCT improved/stable in 76%. Dyspnoea stable/improved in 95%. Abstr#2174 #ACR23 @RheumNow https://t.co/j6SiEzSRif

Long-term abatacept in UIP RA-ILD. 233 patients, median 22 month follow-up. Sustained benefits to previous data. ABA was withdrawn in 50 patients (21.5%) (ILD worsening 20, joint worsening 15, serious infections 7, others 8) Abstr#2165 #ACR23 @RheumNow https://t.co/SinE4GgFRE https://t.co/M1Nnce58OE

Who gives a ‘JAK’ why and how they work, as long as they do! Several abstracts have studied the mechanism of action of JAKi in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. #ACR23 https://t.co/xqQF8SULgp https://t.co/DZtEly8GEq

• Who gives a ‘JAK’ why and how they work, as long as they do! | RheumNow